Volume 5, Issue 5

PrEP and Women

In this issue:

Worldwide, nearly 38 million people are living with the HIV virus. More than half of these are women. PrEP — HIV pre-exposure prophylaxis — has been shown to prevent heterosexual HIV transmission by as much as 92%. But the CDC estimates that 98% of US women at high risk for HIV acquisition have not initiated PrEP.

What can be done to reduce or eliminate HIV transmission in this population? In this issue, Dr. Rachel Scott from the Georgetown University School of Medicine analyzes the current implementation strategies and barriers preventing women from initiating PrEP.

Learning objectives:

  • Discuss the importance of HIV prevention and pre-exposure prophylaxis in women. 
  • Describe systemic and patient-level barriers to PrEP use in women.



Rachel Scott, MD, MPH
Rachel Scott, MD, MPH

Scientific Director of Women's Health Research, MedStar Health Research Institute
Associate Chair for Research in the Department of Women’s and Infants’ Services at MedStar Washington Hospital Center
Assistant Professor of Obstetrics and Gynecology, Georgetown University School of Medicine
MedStar Health Research Institute/Washington Hospital Center and Georgetown University School of Medicine

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: April 3, 2020
Expiration date: April 2, 2022